Roland Tubiana
Overview
Explore the profile of Roland Tubiana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
1728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montrouge T, Bertine M, Peytavin G, Saint Joannis T, Bachelard A, De Truchis P, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39737782
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with...
2.
Soulie C, Agher R, Fauchois A, Abdi B, Wirden M, Teyssou E, et al.
J Antimicrob Chemother
. 2024 Dec;
80(3):697-700.
PMID: 39704180
Background: We aimed to determine how non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance profiles have changed over the last decade in people living with HIV (PLWHIV) experiencing virological failure on all...
3.
Mandelbrot L, Tubiana R, Frange P, Peytavin G, Chenadec J, Canestri A, et al.
J Antimicrob Chemother
. 2023 May;
78(7):1711-1722.
PMID: 37248782
Objectives: Because NRTIs can have fetal toxicities, we evaluated a perinatal NRTI-sparing strategy to prevent perinatal HIV transmission. Our primary objective was to determine the proportion maintaining a viral load...
4.
Berot V, Eremin A, Fauchois A, Dechamp J, Schneider L, Chermak A, et al.
Sex Transm Infect
. 2023 May;
99(5):361-362.
PMID: 37173130
No abstract available.
5.
Sellem B, Abdi B, Le M, Tubiana R, Valantin M, Seang S, et al.
J Pers Med
. 2023 Apr;
13(4).
PMID: 37108969
In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV...
6.
de Villartay J, Pannier E, Sibiude J, Frange P, Tubiana R, Blanche S
J Acquir Immune Defic Syndr
. 2022 Nov;
92(3):260-262.
PMID: 36343360
Effectiveness of anti-HIV in the prevention of perinatal transmission has been established. Assessing the tolerance of drug exposure during pregnancy is of the utmost importance given the number of children...
7.
Palich R, Agher R, Wetshikoy D, Cuzin L, Seang S, Soulie C, et al.
J Acquir Immune Defic Syndr
. 2022 Oct;
92(2):144-152.
PMID: 36257296
Objectives: To assess whether antiretroviral therapy (ART) prescriptions differ between naive and virally suppressed HIV patients born in France (PBFs) and in Sub-Saharan Africa (PBSSAs). Setting: Observational single-center study. Methods:...
8.
Sibiude J, Chenadec J, Mandelbrot L, Hoctin A, Dollfus C, Faye A, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e590-e598.
PMID: 36037040
Background: Antiretroviral therapy (ART) is remarkably effective in preventing perinatal transmission (PT) of HIV-1. We evaluated the PT rate in a population of women with widespread access to ART before...
9.
Breton G, Cisse M, Diallo O, Diallo N, Soumaoro S, Camara Y, et al.
J Antimicrob Chemother
. 2022 Aug;
77(11):3093-3101.
PMID: 36031792
Background: Nearly half of HIV-infected children worldwide are born in West and Central African countries where access to prevention of mother-to-child transmission of HIV (PMTCT) programmes is still limited. WHO...
10.
Pourcher V, Belin L, Soulie C, Rosenzwajg M, Marot S, Lacombe K, et al.
AIDS
. 2022 Jun;
36(11):1545-1552.
PMID: 35730380
Objectives: To assess humoral responses to SARS-CoV-2 Delta-variant in people with HIV (PWH) after BNT162b2-vaccination. Design: Multicenter cohort study of PWH with CD4 + cell count less than 500 cells/μl...